Skip to main content
Top
Published in: Current Rheumatology Reports 3/2017

01-03-2017 | Spondyloarthritis (M Khan, Section Editor)

Structural Disease Progression in Axial Spondyloarthritis: Still a Cause for Concern?

Authors: Barbara Neerinckx, Rik J. Lories

Published in: Current Rheumatology Reports | Issue 3/2017

Login to get access

Abstract

Purpose of the Review

Progressive ankylosis is a feared consequence of long-standing axial spondyloarthritis. We aim to critically review current insights into the effect of therapy, the molecular pathways involved in this process, and to present a model explaining the sequence of events.

Recent Findings

Long-term follow-up data suggest that successful control of inflammation may slow down radiographic progression of disease in axial spondyloarthritis. Structural effects of new therapies such as interleukin-17 targeting need to be further studied. Bone loss and architectural changes could act as driver for the tissue remodeling process trying to maintain spinal stability in the presence of inflammation.

Summary

Despite some progress, the nature and mechanisms of new bone formation in axial spondyloarthritis still remain incompletely understood. However, long-term control of inflammation appears critical to avoid progressive disability due to structural damage.
Literature
2.
go back to reference Poddubnyy D, Rudwaleit M, Haibel H, Listing J, Marker-Hermann E, Zeidler H, et al. Rates and predictors of radiographic sacroiliitis progression over 2 years in patients with axial spondyloarthritis. Ann Rheum Dis. 2011;70(8):1369–74. doi:10.1136/ard.2010.145995.CrossRefPubMed Poddubnyy D, Rudwaleit M, Haibel H, Listing J, Marker-Hermann E, Zeidler H, et al. Rates and predictors of radiographic sacroiliitis progression over 2 years in patients with axial spondyloarthritis. Ann Rheum Dis. 2011;70(8):1369–74. doi:10.​1136/​ard.​2010.​145995.CrossRefPubMed
3.
go back to reference Machado P, Landewe R, Braun J, Hermann KG, Baker D, van der Heijde D. Both structural damage and inflammation of the spine contribute to impairment of spinal mobility in patients with ankylosing spondylitis. Ann Rheum Dis. 2010;69(8):1465–70. doi:10.1136/ard.2009.124206.CrossRefPubMed Machado P, Landewe R, Braun J, Hermann KG, Baker D, van der Heijde D. Both structural damage and inflammation of the spine contribute to impairment of spinal mobility in patients with ankylosing spondylitis. Ann Rheum Dis. 2010;69(8):1465–70. doi:10.​1136/​ard.​2009.​124206.CrossRefPubMed
4.
go back to reference • Callhoff J, Sieper J, Weiss A, Zink A, Listing J. Efficacy of TNFalpha blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis. Ann Rheum Dis. 2015;74(6):1241–8. doi:10.1136/annrheumdis-2014-205322. This study provides an interesting summary on the use of TNF inhibitors in axial SpA.CrossRefPubMed • Callhoff J, Sieper J, Weiss A, Zink A, Listing J. Efficacy of TNFalpha blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis. Ann Rheum Dis. 2015;74(6):1241–8. doi:10.​1136/​annrheumdis-2014-205322. This study provides an interesting summary on the use of TNF inhibitors in axial SpA.CrossRefPubMed
5.
go back to reference Baeten D, Baraliakos X, Braun J, Sieper J, Emery P, van der Heijde D, et al. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet. 2013;382(9906):1705–13. doi:10.1016/S0140-6736(13)61134-4.CrossRefPubMed Baeten D, Baraliakos X, Braun J, Sieper J, Emery P, van der Heijde D, et al. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet. 2013;382(9906):1705–13. doi:10.​1016/​S0140-6736(13)61134-4.CrossRefPubMed
7.
go back to reference Poddubnyy D, Hermann KG, Callhoff J, Listing J, Sieper J. Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS). Ann Rheum Dis. 2014;73(5):817–23. doi:10.1136/annrheumdis-2013-204248.CrossRefPubMed Poddubnyy D, Hermann KG, Callhoff J, Listing J, Sieper J. Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS). Ann Rheum Dis. 2014;73(5):817–23. doi:10.​1136/​annrheumdis-2013-204248.CrossRefPubMed
9.
go back to reference Maksymowych WP, Elewaut D, Schett G. Motion for debate: the development of ankylosis in ankylosing spondylitis is largely dependent on inflammation. Arthritis Rheum. 2012;64(6):1713–9. doi:10.1002/art.34442.CrossRefPubMed Maksymowych WP, Elewaut D, Schett G. Motion for debate: the development of ankylosis in ankylosing spondylitis is largely dependent on inflammation. Arthritis Rheum. 2012;64(6):1713–9. doi:10.​1002/​art.​34442.CrossRefPubMed
10.
go back to reference van der Heijde D, Landewe R, Baraliakos X, Houben H, van Tubergen A, Williamson P, et al. Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum. 2008;58(10):3063–70. doi:10.1002/art.23901.CrossRef van der Heijde D, Landewe R, Baraliakos X, Houben H, van Tubergen A, Williamson P, et al. Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum. 2008;58(10):3063–70. doi:10.​1002/​art.​23901.CrossRef
11.
go back to reference van der Heijde D, Landewe R, Einstein S, Ory P, Vosse D, Ni L, et al. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum. 2008;58(5):1324–31. doi:10.1002/art.23471.CrossRefPubMed van der Heijde D, Landewe R, Einstein S, Ory P, Vosse D, Ni L, et al. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum. 2008;58(5):1324–31. doi:10.​1002/​art.​23471.CrossRefPubMed
12.
go back to reference van der Heijde D, Salonen D, Weissman BN, Landewe R, Maksymowych WP, Kupper H, et al. Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. Arthritis Res Ther. 2009;11(4):R127. doi:10.1186/ar2794.CrossRefPubMedPubMedCentral van der Heijde D, Salonen D, Weissman BN, Landewe R, Maksymowych WP, Kupper H, et al. Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. Arthritis Res Ther. 2009;11(4):R127. doi:10.​1186/​ar2794.CrossRefPubMedPubMedCentral
13.
go back to reference Haroon N, Inman RD, Learch TJ, Weisman MH, Lee M, Rahbar MH, et al. The impact of tumor necrosis factor alpha inhibitors on radiographic progression in ankylosing spondylitis. Arthritis Rheum. 2013;65(10):2645–54. doi:10.1002/art.38070.PubMedPubMedCentral Haroon N, Inman RD, Learch TJ, Weisman MH, Lee M, Rahbar MH, et al. The impact of tumor necrosis factor alpha inhibitors on radiographic progression in ankylosing spondylitis. Arthritis Rheum. 2013;65(10):2645–54. doi:10.​1002/​art.​38070.PubMedPubMedCentral
14.
go back to reference Baraliakos X, Haibel H, Listing J, Sieper J, Braun J. Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis. Ann Rheum Dis. 2014;73(4):710–5. doi:10.1136/annrheumdis-2012-202698.CrossRefPubMed Baraliakos X, Haibel H, Listing J, Sieper J, Braun J. Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis. Ann Rheum Dis. 2014;73(4):710–5. doi:10.​1136/​annrheumdis-2012-202698.CrossRefPubMed
15.
go back to reference • Maas F, Arends S, Brouwer E, Essers I, van der Veer E, Efde M et al. Reduction in spinal radiographic progression in ankylosing spondylitis patients receiving prolonged treatment with TNF-alpha inhibitors. Arthritis Care Res (Hoboken). 2016. doi:10.1002/acr.23097. Novel data about the potential effects of anti-TNF on radiographic progression. • Maas F, Arends S, Brouwer E, Essers I, van der Veer E, Efde M et al. Reduction in spinal radiographic progression in ankylosing spondylitis patients receiving prolonged treatment with TNF-alpha inhibitors. Arthritis Care Res (Hoboken). 2016. doi:10.​1002/​acr.​23097. Novel data about the potential effects of anti-TNF on radiographic progression.
16.
go back to reference Song IH, Hermann KG, Haibel H, Althoff CE, Poddubnyy D, Listing J, et al. Prevention of new osteitis on magnetic resonance imaging in patients with early axial spondyloarthritis during 3 years of continuous treatment with etanercept: data of the ESTHER trial. Rheumatology (Oxford). 2015;54(2):257–61. doi:10.1093/rheumatology/keu263.CrossRef Song IH, Hermann KG, Haibel H, Althoff CE, Poddubnyy D, Listing J, et al. Prevention of new osteitis on magnetic resonance imaging in patients with early axial spondyloarthritis during 3 years of continuous treatment with etanercept: data of the ESTHER trial. Rheumatology (Oxford). 2015;54(2):257–61. doi:10.​1093/​rheumatology/​keu263.CrossRef
18.
go back to reference Wanders A, Heijde D, Landewe R, Behier JM, Calin A, Olivieri I, et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum. 2005;52(6):1756–65. doi:10.1002/art.21054.CrossRefPubMed Wanders A, Heijde D, Landewe R, Behier JM, Calin A, Olivieri I, et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum. 2005;52(6):1756–65. doi:10.​1002/​art.​21054.CrossRefPubMed
19.
go back to reference Poddubnyy D, Rudwaleit M, Haibel H, Listing J, Marker-Hermann E, Zeidler H, et al. Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. Ann Rheum Dis. 2012;71(10):1616–22. doi:10.1136/annrheumdis-2011-201252.CrossRefPubMed Poddubnyy D, Rudwaleit M, Haibel H, Listing J, Marker-Hermann E, Zeidler H, et al. Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. Ann Rheum Dis. 2012;71(10):1616–22. doi:10.​1136/​annrheumdis-2011-201252.CrossRefPubMed
20.
go back to reference •• Sieper J, Listing J, Poddubnyy D, Song IH, Hermann KG, Callhoff J, et al. Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2 years on radiographic progression of the spine: results from a randomised multicentre trial (ENRADAS). Ann Rheum Dis. 2016;75(8):1438–43. doi:10.1136/annrheumdis-2015-207897. Important data about the difficulties to demonstrate a structure modifying effect of NSAID therapy.CrossRefPubMed •• Sieper J, Listing J, Poddubnyy D, Song IH, Hermann KG, Callhoff J, et al. Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2 years on radiographic progression of the spine: results from a randomised multicentre trial (ENRADAS). Ann Rheum Dis. 2016;75(8):1438–43. doi:10.​1136/​annrheumdis-2015-207897. Important data about the difficulties to demonstrate a structure modifying effect of NSAID therapy.CrossRefPubMed
24.
go back to reference Maksymowych WP, Morency N, Conner-Spady B, Lambert RG. Suppression of inflammation and effects on new bone formation in ankylosing spondylitis: evidence for a window of opportunity in disease modification. Ann Rheum Dis. 2013;72(1):23–8. doi:10.1136/annrheumdis-2011-200859.CrossRefPubMed Maksymowych WP, Morency N, Conner-Spady B, Lambert RG. Suppression of inflammation and effects on new bone formation in ankylosing spondylitis: evidence for a window of opportunity in disease modification. Ann Rheum Dis. 2013;72(1):23–8. doi:10.​1136/​annrheumdis-2011-200859.CrossRefPubMed
25.
go back to reference Maksymowych WP, Wichuk S, Chiowchanwisawakit P, Lambert RG, Pedersen SJ. Fat metaplasia and backfill are key intermediaries in the development of sacroiliac joint ankylosis in patients with ankylosing spondylitis. Arthritis Rheumatol. 2014;66(11):2958–67. doi:10.1002/art.38792.CrossRefPubMed Maksymowych WP, Wichuk S, Chiowchanwisawakit P, Lambert RG, Pedersen SJ. Fat metaplasia and backfill are key intermediaries in the development of sacroiliac joint ankylosis in patients with ankylosing spondylitis. Arthritis Rheumatol. 2014;66(11):2958–67. doi:10.​1002/​art.​38792.CrossRefPubMed
26.
go back to reference Chiowchanwisawakit P, Lambert RGW, Conner-Spady B, Maksymowych WP. Focal fat lesions at vertebral corners on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis. Arthritis Rheum-Us. 2011;63(8):2215–25. doi:10.1002/art.30393.CrossRef Chiowchanwisawakit P, Lambert RGW, Conner-Spady B, Maksymowych WP. Focal fat lesions at vertebral corners on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis. Arthritis Rheum-Us. 2011;63(8):2215–25. doi:10.​1002/​art.​30393.CrossRef
27.
go back to reference •• Machado PM, Baraliakos X, van der Heijde D, Braun J, Landewe R. MRI vertebral corner inflammation followed by fat deposition is the strongest contributor to the development of new bone at the same vertebral corner: a multilevel longitudinal analysis in patients with ankylosing spondylitis. Ann Rheum Dis. 2016;75(8):1486–93. doi:10.1136/annrheumdis-2015-208011. The paper provides good evidence for a sequential process leading to ankylosis.CrossRefPubMed •• Machado PM, Baraliakos X, van der Heijde D, Braun J, Landewe R. MRI vertebral corner inflammation followed by fat deposition is the strongest contributor to the development of new bone at the same vertebral corner: a multilevel longitudinal analysis in patients with ankylosing spondylitis. Ann Rheum Dis. 2016;75(8):1486–93. doi:10.​1136/​annrheumdis-2015-208011. The paper provides good evidence for a sequential process leading to ankylosis.CrossRefPubMed
28.
go back to reference Baraliakos X, Heldmann F, Callhoff J, Listing J, Appelboom T, Brandt J, et al. Which spinal lesions are associated with new bone formation in patients with ankylosing spondylitis treated with anti-TNF agents? A long-term observational study using MRI and conventional radiography. Ann Rheum Dis. 2014;73(10):1819–25. doi:10.1136/annrheumdis-2013-203425.CrossRefPubMed Baraliakos X, Heldmann F, Callhoff J, Listing J, Appelboom T, Brandt J, et al. Which spinal lesions are associated with new bone formation in patients with ankylosing spondylitis treated with anti-TNF agents? A long-term observational study using MRI and conventional radiography. Ann Rheum Dis. 2014;73(10):1819–25. doi:10.​1136/​annrheumdis-2013-203425.CrossRefPubMed
29.
go back to reference •• Baraliakos X, Boehm H, Samir A, Schett G, Braun J. Which cells correspond to typical signals for fatty and inflammatory lesions seen on MRI in AS? Clin Exp Rheumatol. 2016;34(4):744. New knowledge on the histological appearance of fatty lesions on MRI in SpA. •• Baraliakos X, Boehm H, Samir A, Schett G, Braun J. Which cells correspond to typical signals for fatty and inflammatory lesions seen on MRI in AS? Clin Exp Rheumatol. 2016;34(4):744. New knowledge on the histological appearance of fatty lesions on MRI in SpA.
30.
go back to reference van der Heijde D, Machado P, Braun J, Hermann KGA, Baraliakos X, Hsu B, et al. MRI inflammation at the vertebral unit only marginally predicts new syndesmophyte formation: a multilevel analysis in patients with ankylosing spondylitis. Ann Rheum Dis. 2012;71(3):369–73. doi:10.1136/annrheumdis-2011-200208.CrossRefPubMed van der Heijde D, Machado P, Braun J, Hermann KGA, Baraliakos X, Hsu B, et al. MRI inflammation at the vertebral unit only marginally predicts new syndesmophyte formation: a multilevel analysis in patients with ankylosing spondylitis. Ann Rheum Dis. 2012;71(3):369–73. doi:10.​1136/​annrheumdis-2011-200208.CrossRefPubMed
31.
go back to reference Sherlock JP, Joyce-Shaikh B, Turner SP, Chao CC, Sathe M, Grein J, et al. IL-23 induces spondyloarthropathy by acting on ROR-gammat+ CD3+CD4-CD8- entheseal resident T cells. Nat Med. 2012;18(7):1069–76. doi:10.1038/nm.2817.CrossRefPubMed Sherlock JP, Joyce-Shaikh B, Turner SP, Chao CC, Sathe M, Grein J, et al. IL-23 induces spondyloarthropathy by acting on ROR-gammat+ CD3+CD4-CD8- entheseal resident T cells. Nat Med. 2012;18(7):1069–76. doi:10.​1038/​nm.​2817.CrossRefPubMed
32.
go back to reference El-Sherbiny Y, Elzayadi A, Fragkakis EM, Cuthbert R, Baboolal T, Jones E et al. IL-22 drives the proliferation and differentiation of human bone marrow mesenchymal stem cells (MSCs); a novel pathway that may contribute to aberrant new bone formation in human spa and beyond. Arthritis & Rheumatology. 2015;67 El-Sherbiny Y, Elzayadi A, Fragkakis EM, Cuthbert R, Baboolal T, Jones E et al. IL-22 drives the proliferation and differentiation of human bone marrow mesenchymal stem cells (MSCs); a novel pathway that may contribute to aberrant new bone formation in human spa and beyond. Arthritis & Rheumatology. 2015;67
35.
40.
go back to reference Heiland GR, Appel H, Poddubnyy D, Zwerina J, Hueber A, Haibel H, et al. High level of functional dickkopf-1 predicts protection from syndesmophyte formation in patients with ankylosing spondylitis. Ann Rheum Dis. 2012;71(4):572–4. doi:10.1136/annrheumdis-2011-200216.CrossRefPubMed Heiland GR, Appel H, Poddubnyy D, Zwerina J, Hueber A, Haibel H, et al. High level of functional dickkopf-1 predicts protection from syndesmophyte formation in patients with ankylosing spondylitis. Ann Rheum Dis. 2012;71(4):572–4. doi:10.​1136/​annrheumdis-2011-200216.CrossRefPubMed
41.
go back to reference Daoussis D, Liossis SN, Solomou EE, Tsanaktsi A, Bounia K, Karampetsou M, et al. Evidence that Dkk-1 is dysfunctional in ankylosing spondylitis. Arthritis Rheum. 2010;62(1):150–8. doi:10.1002/art.27231.CrossRefPubMed Daoussis D, Liossis SN, Solomou EE, Tsanaktsi A, Bounia K, Karampetsou M, et al. Evidence that Dkk-1 is dysfunctional in ankylosing spondylitis. Arthritis Rheum. 2010;62(1):150–8. doi:10.​1002/​art.​27231.CrossRefPubMed
42.
go back to reference Yucong Z, Lu L, Shengfa L, Yongliang Y, Ruguo S, Yikai L. Serum functional dickkopf-1 levels are inversely correlated with radiographic severity of ankylosing spondylitis. Clin Lab. 2014;60(9):1527–31.PubMed Yucong Z, Lu L, Shengfa L, Yongliang Y, Ruguo S, Yikai L. Serum functional dickkopf-1 levels are inversely correlated with radiographic severity of ankylosing spondylitis. Clin Lab. 2014;60(9):1527–31.PubMed
46.
go back to reference •• Cortes A, Maksymowych WP, Wordsworth BP, Inman RD, Danoy P, Rahman P, et al. Association study of genes related to bone formation and resorption and the extent of radiographic change in ankylosing spondylitis. Ann Rheum Dis. 2015;74(7):1387–93. doi:10.1136/annrheumdis-2013-204835. First study to link specific genes to disease progression in SpA.CrossRefPubMed •• Cortes A, Maksymowych WP, Wordsworth BP, Inman RD, Danoy P, Rahman P, et al. Association study of genes related to bone formation and resorption and the extent of radiographic change in ankylosing spondylitis. Ann Rheum Dis. 2015;74(7):1387–93. doi:10.​1136/​annrheumdis-2013-204835. First study to link specific genes to disease progression in SpA.CrossRefPubMed
47.
go back to reference • Nigil Haroon N, Szabo E, Raboud JM, McDonald-Blumer H, Fung L, Josse RG, et al. Alterations of bone mineral density, bone microarchitecture and strength in patients with ankylosing spondylitis: a cross-sectional study using high-resolution peripheral quantitative computerized tomography and finite element analysis. Arthritis Res Ther. 2015;17:377. doi:10.1186/s13075-015-0873-1. A novel approach to asses structural changes in axial spondyloarthritis.CrossRefPubMedPubMedCentral • Nigil Haroon N, Szabo E, Raboud JM, McDonald-Blumer H, Fung L, Josse RG, et al. Alterations of bone mineral density, bone microarchitecture and strength in patients with ankylosing spondylitis: a cross-sectional study using high-resolution peripheral quantitative computerized tomography and finite element analysis. Arthritis Res Ther. 2015;17:377. doi:10.​1186/​s13075-015-0873-1. A novel approach to asses structural changes in axial spondyloarthritis.CrossRefPubMedPubMedCentral
Metadata
Title
Structural Disease Progression in Axial Spondyloarthritis: Still a Cause for Concern?
Authors
Barbara Neerinckx
Rik J. Lories
Publication date
01-03-2017
Publisher
Springer US
Published in
Current Rheumatology Reports / Issue 3/2017
Print ISSN: 1523-3774
Electronic ISSN: 1534-6307
DOI
https://doi.org/10.1007/s11926-017-0639-7

Other articles of this Issue 3/2017

Current Rheumatology Reports 3/2017 Go to the issue

Systemic Lupus Erythematosus (G Tsokos, Section Editor)

ApoL1 and the Immune Response of Patients with Systemic Lupus Erythematosus

Systemic Lupus Erythematosus (G Tsokos, Section Editor)

Novel Treatments in Lupus

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.